Explore Treatments for Stiff-Person Syndrome (SPS)

Stiff-person syndrome (SPS), also called Stiff-Man Syndrome (SMS) or Moersch-Woltman Syndrome, is a rare neurological disorder that causes episodes of muscle stiffness (rigidity) and painful spasms. These symptoms often begin in the back but can affect the arms, legs, and other parts of the body. The muscle stiffness may cause a person to stand or walk with a stiff or hunched posture. Episodes of spasm and stiffness can come and go but usually get worse over time. This can lead to chronic pain, difficulty moving, and in severe cases, breathing problems that require medical attention. The exact cause of SPS is unknown, but it is believed to be an autoimmune condition that affects the brain and spinal cord (central nervous system). SPS can also occur alongside other autoimmune diseases or certain types of cancer.

Treatments Offered by CSI

Immunoglobulins are derived from pooled human plasma collected from thousands of carefully screened donors. The plasma is rigorously processed and purified to ensure product safety and integrity. Intravenous immunoglobulin (IVIG) contains antibodies that provide broad protection against a wide range of bacteria and viruses. It is administered intravenously and is primarily used to treat three categories of conditions: primary immunodeficiency diseases, autoimmune disorders, and certain neurological conditions. 

  • Alyglo 10% 
  • Asceniv 10% 
  • Bivigam 10% 
  • Gammagard S/D 
  • Gammagard Liquid 10% 
  • Gammaked 10% 
  • Gamunex-C 10% 
  • Gammaplex 5% 
  • Gammaplex 10% 
  • Octagam 5% 
  • Octagam 10% 
  • Panzyga 10% 
  • Privigen 10% 
  • Yimmugo 10% 

Immunoglobulins are derived from pooled human plasma collected from thousands of carefully screened donors. The plasma undergoes rigorous processing and purification to ensure the highest standards of safety and product integrity. Subcutaneous immunoglobulin (SCIG) contains antibodies that offer broad protection against a wide range of bacteria and viruses. It is administered under the skin (subcutaneously) and is primarily used to treat primary immunodeficiency diseases and chronic inflammatory demyelinating polyneuropathy (CIDP). SCIG is also being studied in clinical trials for use in additional conditions. 

  • Cutaquig 16.5%  
  • Cuvitru 20% 
  • Gammagard Liquid 10% 
  • Gammaked 10% 
  • Gamunex-C 10% 
  • Hizentra 20% 
  • HyQvia 10% (facilitated SCIG)  
  • Xembify 20%